B-CELL LYMPHOMA

This early-phase study tests a new type of CAR T-cell therapy for adults with large B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to find a …

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors.…

This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along wi…

This study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain B-cell blood cancers who are getting CAR-T treatment will receive anakinra. The goal i…

This early-phase study tests a new type of CAR T-cell therapy that targets three different markers on cancer cells (CD19, CD20, and CD22) to treat people with B-cell lymphomas that have come back or not responded to standard treatments. About 15 adults will receive these speciall…

This early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer ce…

This study was designed to test a new treatment called BAFFR CAR-T for people with B-cell blood cancers that came back or didn't respond to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. However, the trial was withdrawn before en…

This study aimed to see if the drug glofitamab could prevent large B-cell lymphoma from returning in patients who had traces of cancer after standard treatment. It was designed for adults who had completed first-line therapy and still had minimal residual disease. However, the tr…

This early-phase trial tests the safety of giving specially modified T-cells from a donor to people with B-cell leukemia or lymphoma that has returned after a stem cell or organ transplant. The modified cells are designed to target a protein called CD19 on cancer cells. Only 19 p…

This phase II trial tests a combination of two drugs, palbociclib and ibrutinib, in 39 patients with mantle cell lymphoma that has come back after prior treatment. The goal is to see if the combo can delay cancer progression. Patients take both pills daily in 28-day cycles. The s…

This study aimed to test a new CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The therapy was designed to help the immune system attack the cancer. However, the tri…

This early-phase study tests a new drug, loncastuximab tesirine, added to a standard chemotherapy regimen (DA-EPOCH-R) for adults with aggressive B-cell lymphomas, including Burkitt lymphoma. The main goal is to find the safest dose by monitoring side effects. Only 11 participant…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…

This early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …

This study follows about 178 people who previously received AvenCell's CAR-T cell therapy for blood cancers or prostate cancer. The goal is to monitor long-term safety, including delayed side effects like new cancers or autoimmune problems. Participants are not receiving new trea…

This study looks at whether a blood test (liquid biopsy) can predict if lymphoma will come back within 1-2 years after first treatment, compared to the usual PET-CT scan. Researchers will follow 108 adults with B-cell or Hodgkin lymphoma after their first therapy. The goal is to …

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…